

Bibliografía

1. International Agency for Reserch on Cancer. Estimated Incidence, Mortality and Prevalence Worldwide in 2012 Lyon, France2012 [http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx].
2. World Health Organization. The top 10 causes of death. Fact sheet N°310Updated May 2014.
3. Depatamento Administrativo Nacional de Estadística. Estadísticas Vitales Nacimientos y Defunciones. Bogotá: Gobierno de Colombia; 2014.
4. Buffery D. Health Economics in Oncology: A Necessary Tool for Value-Based Patient Care. *American Health & Drug Benefits*. 2015;8(4):184-.
5. Ministerio de Salud y Protección Social, Colombia. Por el cual se sustituye el Acuerdo 028 de 2011 que define, aclara y actualiza integralmente el Plan Obligatorio de Salud. In: *Salud CdRe*, editor. Bogotá2011.
6. Ministerio de Salud y Protección Social, Colombia. PLAN DECENAL PARA EL CONTROL DEL CÁNCER EN COLOMBIA, 2012-2021. In: *cancerología Ind*, editor. 2012.
7. Ministerio de Salud y Protección Social, Colombia. RESOLUCIÓN NÚMERO 000247 DE 2014. Por la cual se establece el reporte para el registro de pacientes con cáncer. Bogotá: MSPS; 2014.
8. National Cancer Institute. NCI Dictionary of Cancer Terms <http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=462642016> [Definición de términos en cáncer].
9. Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes: Module 1: Planning. Geneva: World Health Organization, Copyright (c) World Health Organization 2006.; 2006.
10. Miller JD, Foley KA, Russell MW. Current challenges in health economic modeling of cancer therapies: a research inquiry. *Am Health Drug Benefits*. 2014;7(3):153-62.
11. Instituto Nacional de Salud, Colombia . Aspectos relacionados con al frecuencia de uso de los servicios de salud, mortalidad y discapacidad en Colombia 2011. Bogotá D.C., Colombia: Imprenta Nacional de Colombia; 2013.
12. Wong E. INTRODUCTION TO NEOPLASIA http://www.pathophys.org/introneoplasia/#Chapter_1_Introduction_to_neoplasia: Mc Master Pathophysiology Review; 2016
13. Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes: Module 3: Early Detection. Geneva: World Health Organization Copyright (c) World Health Organization 2007.; 2007.
14. Rid A. Just health: meeting health needs fairly. *Bulletin of the World Health Organization*. 2008;86(8):653.
15. Satyanarayana L, Asthana S, Labani SP. Childhood cancer incidence in India: a review of population-based cancer registries. *Indian Pediatr*. 2014;51(3):218-20.
16. American Cancer Society, *Cancer facts and figures 2014*.
17. Lacour B, Guyot-Goubin A, Guissou S, Bellec S, Desandes E, Clavel J. Incidence of childhood cancer in France: National Children Cancer Registries, 2000-2004. *Eur J Cancer Prev*. 2010;19(3):173-81.
18. F. CRGJLAA. *The Surgery of Childhood Tumors*. Springer-Verlag Berlin Heidelberg; 2008. p. XXVI 626
19. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to Therapy With Oral Antineoplastic Agents. *Journal of the National Cancer Institute*. 2002;94(9):652-61.
20. Morden NE, Goodman D. Pediatric polypharmacy: time to lock the medicine cabinet? *Arch Pediatr Adolesc Med*. 166. United States2012. p. 91-2.
21. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. *Cancer*.

2005;104(6):1129-37.

22. Michel G. Leucemia linfoblástica aguda del niño y del adolescente: clínica y tratamiento. EMC - Pediatría. 2008;43(4):1-11.
23. International agency for reserch on cancer. 9835/3 ACUTE LYMPHOCYTIC LEUKEMIA <http://codes.iarc.fr/code/4207> - Lyon, France: International Agency for Reserch on Cancer; [
24. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-43.
25. Vizcaíno M, Lopera JE, Martínez L, Reyes IDI, Linares A. Guía de atención integral para la detección oportuna, diagnóstico, tratamiento y seguimiento de leucemia linfocítica aguda en niños, niñas y adolescentes. Revista Colombiana de Cancerología. 2016;20(01):17-27.
26. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. New England Journal of Medicine. 2015;373(16):1541-52.
27. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER Cancer Statistics Review 1975-2010 Bethesda, http://seer.cancer.gov/csr/1975_2010/: National Cancer Institute; 2016
28. Clavel J, Goubin A, Auclerc MF, Auvrignon A, Waterkeyn C, Patte C, et al. Incidence of childhood leukaemia and non-Hodgkin's lymphoma in France: National Registry of Childhood Leukaemia and Lymphoma, 1990-1999. Eur J Cancer Prev. 2004;13(2):97-103.
29. Alexander S. Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014;2014(1):181-9.
30. Klasner A. Chapter 45 - Brain Tumor A2 - Baren, Jill M. In: Rothrock SG, Brennan JA, Brown L, editors. Pediatric Emergency Medicine. Philadelphia: W.B. Saunders; 2008. p. 385-7.
31. Mehta V, Chapman A, McNeely PD, Walling S, Howes WJ. Latency between symptom onset and diagnosis of pediatric brain tumors: an Eastern Canadian geographic study. Neurosurgery. 2002;51(2):365-72; discussion 72-3.
32. Perry J, Zinman L, Chambers A, Spithoff K, Lloyd N, Laperriere N. The use of prophylactic anticonvulsants in patients with brain tumours a systematic review. Curr Oncol. 2006;13(6):222-9.
33. Shamberger RC. chapter 67 - RENAL TUMORS A2 - Holcomb, George Whitfield. In: Murphy JP, Editor A, Ostlie DJ, editors. Ashcraft's Pediatric Surgery (Fifth edition). Philadelphia: W.B. Saunders; 2010. p. 853-71.
34. Geller E, Kochan PS. Renal Neoplasms of Childhood. Radiologic Clinics of North America. 2011;49(4):689-709.
35. Young G, Toretzky JA, Campbell AB, Eskenazi AE. Recognition of common childhood malignancies. Am Fam Physician. 2000;61(7):2144-54.
36. Sandlund JT. Non-Hodgkin Lymphoma in Children. Curr Hematol Malig Rep. 2015;10(3):237-43.
37. Pui C-H, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165-74.
38. Izarzugaza MI, Steliarova-Foucher E, Martos MC, Zivkovic S. Non-Hodgkin's lymphoma incidence and survival in European children and adolescents (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2050-63.
39. Allen CE, Kelly KM, Bollard CM. Pediatric Lymphomas and Histiocytic Disorders of Childhood. Pediatric Clinics of North America. 2015;62(1):139-65.
40. Sauvaget C, Nishino Y, Konno R, Tase T, Morimoto T, Hisamichi S. Challenges in breast and cervical cancer control in Japan. Lancet Oncol. 2016;17(7):e305-12.
41. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. Bmj. 2000;321(7261):624-8.
42. Greene FL, Sobin LH. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin. 2008;58(3):180-90.
43. Howard JH, Bland KI. Current management and treatment strategies for breast cancer. Curr Opin Obstet Gynecol. 2012;24(1):44-8.
44. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866-71.
45. American Joint Committee on Cancer: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al., editors. AJCC Cancer Staging Manual. New York, NY: Springer New York; 2002. p. 309-

- 16.
46. National Cancer Institute. Tumor Grade <http://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet#r12016>
 47. Mikuz G. Histologic classification of prostate cancer. *Anal Quant Cytopathol Histopathol*. 2015;37(1):39-47.
 48. Kryvenko ON, Epstein JI. Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. *Arch Pathol Lab Med*. 2016.
 49. World Health Organization, Michael F. *Antiandrogens in the Treatment of Prostate Cancer*. Dresden, Germany: European Association of Urology; 2007.
 50. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. *J Clin Endocrinol Metab*. 2002;87(2):599-603.
 51. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. *J Womens Health (Larchmt)*. 2012;21(10):1031-7.
 52. Sherris J, Herdman C, Elias C. Cervical cancer in the developing world. *West J Med*. 2001;175(4):231-3.
 53. National Cancer Institute, Physician Data Query. *Cervical Cancer Treatment (PDQ(R)): Health Professional Version*. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002.
 54. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, et al. Cervical Cancer, Version 2.2015. *J Natl Compr Canc Netw*. 2015;13(4):395-404; quiz
 55. Hamman MK, Kapinos KA. Colorectal Cancer Screening and State Health Insurance Mandates. *Health Econ*. 2016;25(2):178-91.
 56. Brenner H, Kloor M, Pox CP. Colorectal cancer. *Lancet*. 2014;383(9927):1490-502.
 57. Hagggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colon Rectal Surg*. 2009;22(4):191-7.
 58. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. *N Engl J Med*. 2009;361(25):2449-60.
 59. Akkoca AN, Yanik S, Ozdemir ZT, Cihan FG, Sayar S, Cincin TG, et al. TNM and Modified Dukes staging along with the demographic characteristics of patients with colorectal carcinoma. *Int J Clin Exp Med*. 2014;7(9):2828-35.
 60. Edwards MS, Chadda SD, Zhao Z, Barber BL, Sykes DP. A systematic review of treatment guidelines for metastatic colorectal cancer. *Colorectal Dis*. 2012;14(2):e31-47.
 61. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med*. 2006;355(1):11-20.
 62. Carcas LP. Gastric cancer review. *J Carcinog*. 2014;13:14.
 63. Surveillance E, and End Results Program. SEER Stat Fact Sheets: Stomach Cancer <http://seer.cancer.gov/statfacts/html/stomach.html> [
 64. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. *Cancer Epidemiol Biomarkers Prev*. 2014;23(5):700-13.
 65. American Cancer Society. *Chemotherapy for stomach cancer* <http://www.cancer.org/cancer/stomachcancer/detailedguide/stomach-cancer-treating-chemotherapy2014> [
 66. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. *Eur J Cancer*. 1999;35(7):1059-64.
 67. National Cancer Institute. *Adult Non-Hodgkin Lymphoma Treatment (PDQ®)—Patient Version* <http://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq2016> [
 68. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. *Lancet*. 2012;380(9844):848-57.
 69. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Muller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. *Haematologica*. 2016.

70. National Cancer Institute. SEER Stat Fact Sheets: Hodgkin Lymphoma: National Cancer Institute; 2016.
71. Townsend W, Linch D. Hodgkin's lymphoma in adults. *The Lancet*.380(9844):836-47.
72. American Cancer Society. Leukemia–Acute Myeloid (Myelogenous) <http://www.cancer.org/acs/groups/cid/documents/webcontent/003110-pdf.pdf>: American Cancer Society; 2014 [
73. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. *J Clin Oncol*. 2003;21(7):1195-204.
74. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin*. 2014;64(1):9-29.
75. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. *Blood*. 1998;92(7):2322-33.
76. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. *Clin Chest Med*. 2011;32(4):605-44.
77. National Cancer Institute Network . Recent trends in lung cancer incidence, mortality and survival. London: Public Health England; 1993 - 2011.
78. M. H, Kantarjian, Robert A. Wolff, Koller CA. *The MD Anderson Manual of Medical Oncology, 2e*The MD Anderson Manual of Medical Oncology, 2e: McGraw-Hill; 2006.
79. Bjørn R. *Histology of lung cancer Norway*: Oncolex; 2015
80. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl):e278S-313S.
81. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. *Oncologist*. 2011;16(1):5-24.
82. National Cancer Institute. SEER Stat Fact Sheets: Melanoma of the Skin: Surveillance Epidemiology and end results program; 2013 [
83. Marks R. The changing incidence and mortality of melanoma in Australia. *Recent Results Cancer Res*. 2002;160:113-21.
84. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. *Surg Oncol Clin N Am*. 2011;20(1):1-17.
85. Murali R, Desilva C, Thompson JF, Scolyer RA. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. *Ann Surg*. 2011;253(6):1155-64.

